Coherus BioSciences (NASDAQ:CHRS) announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.
Coherus BioSciences shares were trading lower by 13% at $19.77 on Monday morning. The stock has a 52-week high of $23.43 and a 52-week low of $8.32.
Related Links:
Fast Track Designation By FDA Granted For Prevail's Parkinson's Treatment
Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
